ELTROMBOPAG LOW DOSES AS PROPHILAXIS OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) IN CANCER PATIENTS TREATED WITH PLATINUM BASED CHEMOTHERAPY
(Abstract release date: 05/19/16)
EHA Library. Iuliano F. 06/09/16; 132982; E1433
Disclosure(s): I have no conflicts of interest to disclose
Dr. Francesco Iuliano
Contributions
Contributions
Abstract
Abstract: E1433
Type: Eposter Presentation
Background
Chemotherapy-induced thrombocytopenia (CIT) can cause delay or reduction in subsequent courses of chemotherapy. As reported in literature, thrombocytopenia occurred in 82% of those receiving only carboplatin, and in 58%, 64%, and 59% of those receiving combination therapies with carboplatin, gemcitabine or paclitaxel, respectively.Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown efficacy and safety in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy by raising the platelets count in both continued long-term administration and in a repeated short-term administration. Eltrombopag bound the thrombopoietin receptor in the transmembrane region, an area different from where thrombopoietin or romiplostim bound, and activated the thrombopoietin receptor in a different fashion.Here, we report on a series of 18 patients at high risk of CIT because of platinum chemotherapy schedules who received low doses eltrombopag as prophilaxis
Aims
To prevent CIT in patients who cannot be supported by platelet transfusions and for whom the maintenance of dose intensity is crucial for remission or survival
Methods
A total of 18 consecutive adult patients, female (60 %), median age 47 years (range 28 - 65) were enrolled in the study.The reason of chemotherapy has been ovary cancer in 4 patients, colon cancer in 6 patients, relapsed DLBC lymhoma in 4 patients,, TNBC in 2 patients, pancreatic cancer in 2 pts. All patients received eltrombopag 25 mg by mouth twice a weekly as soon as the platelet count falls below 80000 mmc, and continued on treatment until completion of cycles of chemotherapy.
Results
The mean platelet count nadir was 60000 mmc; the number of days with platelet count < 80000/µL was 4 days; The maximum value reached was 270,000 mmc. No treatment-related toxicity was observe. The principal endpoints of the study : avoid nadir platelet counts < 50,000/µL,,platelet transfusions,bleeding events, chemotherapy dose reductions chemotherapy delays. were achieved in all patients.
Conclusion
In our opinion low dose eltrombopag prophilaxis can be an effective and safe strategy for preventing the CIT.
Session topic: E-poster
Keyword(s): Thrombocytopenia, TPO
Type: Eposter Presentation
Background
Chemotherapy-induced thrombocytopenia (CIT) can cause delay or reduction in subsequent courses of chemotherapy. As reported in literature, thrombocytopenia occurred in 82% of those receiving only carboplatin, and in 58%, 64%, and 59% of those receiving combination therapies with carboplatin, gemcitabine or paclitaxel, respectively.Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown efficacy and safety in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy by raising the platelets count in both continued long-term administration and in a repeated short-term administration. Eltrombopag bound the thrombopoietin receptor in the transmembrane region, an area different from where thrombopoietin or romiplostim bound, and activated the thrombopoietin receptor in a different fashion.Here, we report on a series of 18 patients at high risk of CIT because of platinum chemotherapy schedules who received low doses eltrombopag as prophilaxis
Aims
To prevent CIT in patients who cannot be supported by platelet transfusions and for whom the maintenance of dose intensity is crucial for remission or survival
Methods
A total of 18 consecutive adult patients, female (60 %), median age 47 years (range 28 - 65) were enrolled in the study.The reason of chemotherapy has been ovary cancer in 4 patients, colon cancer in 6 patients, relapsed DLBC lymhoma in 4 patients,, TNBC in 2 patients, pancreatic cancer in 2 pts. All patients received eltrombopag 25 mg by mouth twice a weekly as soon as the platelet count falls below 80000 mmc, and continued on treatment until completion of cycles of chemotherapy.
Results
The mean platelet count nadir was 60000 mmc; the number of days with platelet count < 80000/µL was 4 days; The maximum value reached was 270,000 mmc. No treatment-related toxicity was observe. The principal endpoints of the study : avoid nadir platelet counts < 50,000/µL,,platelet transfusions,bleeding events, chemotherapy dose reductions chemotherapy delays. were achieved in all patients.
Conclusion
In our opinion low dose eltrombopag prophilaxis can be an effective and safe strategy for preventing the CIT.
Session topic: E-poster
Keyword(s): Thrombocytopenia, TPO
Abstract: E1433
Type: Eposter Presentation
Background
Chemotherapy-induced thrombocytopenia (CIT) can cause delay or reduction in subsequent courses of chemotherapy. As reported in literature, thrombocytopenia occurred in 82% of those receiving only carboplatin, and in 58%, 64%, and 59% of those receiving combination therapies with carboplatin, gemcitabine or paclitaxel, respectively.Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown efficacy and safety in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy by raising the platelets count in both continued long-term administration and in a repeated short-term administration. Eltrombopag bound the thrombopoietin receptor in the transmembrane region, an area different from where thrombopoietin or romiplostim bound, and activated the thrombopoietin receptor in a different fashion.Here, we report on a series of 18 patients at high risk of CIT because of platinum chemotherapy schedules who received low doses eltrombopag as prophilaxis
Aims
To prevent CIT in patients who cannot be supported by platelet transfusions and for whom the maintenance of dose intensity is crucial for remission or survival
Methods
A total of 18 consecutive adult patients, female (60 %), median age 47 years (range 28 - 65) were enrolled in the study.The reason of chemotherapy has been ovary cancer in 4 patients, colon cancer in 6 patients, relapsed DLBC lymhoma in 4 patients,, TNBC in 2 patients, pancreatic cancer in 2 pts. All patients received eltrombopag 25 mg by mouth twice a weekly as soon as the platelet count falls below 80000 mmc, and continued on treatment until completion of cycles of chemotherapy.
Results
The mean platelet count nadir was 60000 mmc; the number of days with platelet count < 80000/µL was 4 days; The maximum value reached was 270,000 mmc. No treatment-related toxicity was observe. The principal endpoints of the study : avoid nadir platelet counts < 50,000/µL,,platelet transfusions,bleeding events, chemotherapy dose reductions chemotherapy delays. were achieved in all patients.
Conclusion
In our opinion low dose eltrombopag prophilaxis can be an effective and safe strategy for preventing the CIT.
Session topic: E-poster
Keyword(s): Thrombocytopenia, TPO
Type: Eposter Presentation
Background
Chemotherapy-induced thrombocytopenia (CIT) can cause delay or reduction in subsequent courses of chemotherapy. As reported in literature, thrombocytopenia occurred in 82% of those receiving only carboplatin, and in 58%, 64%, and 59% of those receiving combination therapies with carboplatin, gemcitabine or paclitaxel, respectively.Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown efficacy and safety in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy by raising the platelets count in both continued long-term administration and in a repeated short-term administration. Eltrombopag bound the thrombopoietin receptor in the transmembrane region, an area different from where thrombopoietin or romiplostim bound, and activated the thrombopoietin receptor in a different fashion.Here, we report on a series of 18 patients at high risk of CIT because of platinum chemotherapy schedules who received low doses eltrombopag as prophilaxis
Aims
To prevent CIT in patients who cannot be supported by platelet transfusions and for whom the maintenance of dose intensity is crucial for remission or survival
Methods
A total of 18 consecutive adult patients, female (60 %), median age 47 years (range 28 - 65) were enrolled in the study.The reason of chemotherapy has been ovary cancer in 4 patients, colon cancer in 6 patients, relapsed DLBC lymhoma in 4 patients,, TNBC in 2 patients, pancreatic cancer in 2 pts. All patients received eltrombopag 25 mg by mouth twice a weekly as soon as the platelet count falls below 80000 mmc, and continued on treatment until completion of cycles of chemotherapy.
Results
The mean platelet count nadir was 60000 mmc; the number of days with platelet count < 80000/µL was 4 days; The maximum value reached was 270,000 mmc. No treatment-related toxicity was observe. The principal endpoints of the study : avoid nadir platelet counts < 50,000/µL,,platelet transfusions,bleeding events, chemotherapy dose reductions chemotherapy delays. were achieved in all patients.
Conclusion
In our opinion low dose eltrombopag prophilaxis can be an effective and safe strategy for preventing the CIT.
Session topic: E-poster
Keyword(s): Thrombocytopenia, TPO
{{ help_message }}
{{filter}}